Showing results (61-70 of 115) with videos related to
Sort By:
Pageof 12
The Journal of Clinical Investigation|July 24, 2020
The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasisAnne Müller, Antje Dickmanns, Claudia Resch, et al.Cell Reports|November 10, 2016
p53 Activity Results in DNA Replication Fork ProcessivityIna Klusmann, Sabrina Rodewald, Leonie Müller, et al.Cancers|December 24, 2021
HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma CellsKatharina M Ewers, Shilpa Patil, Waltraut Kopp, et al.The Journal of Experimental Medicine|January 25, 2012
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progressionRamona Schulz, Natalia D Marchenko, Lena Holembowski, et al.Oncotarget|October 3, 2015
Usp22 deficiency impairs intestinal epithelial lineage specification in vivoRobyn L Kosinsky, Florian Wegwitz, Nicole Hellbach, et al.Nature|November 24, 2022
MYC multimers shield stalled replication forks from RNA polymeraseDaniel Solvie, Apoorva Baluapuri, Leonie Uhl, et al.Molecular and Cellular Biology|April 16, 2005
Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promotersCarol Imbriano, Aymone Gurtner, Fabienne Cocchiarella, et al.Cell Death and Differentiation|November 12, 2016
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.Cancer Research|December 17, 2008
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrestChristian J Braun, Xin Zhang, Irina Savelyeva, et al.Cell Death and Differentiation|September 5, 2018
Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.Pageof 12